Avelo

What Avelo does

Avelo AG is a privately held Swiss medical device company headquartered in Schlieren, Canton of Zurich, founded in 2020 to develop non-invasive breath sampling technology for diagnosing respiratory infectious diseases. The company's core product is the AveloMask Kit, consisting of a specialized mask with an integrated filter that is worn for approximately 30 minutes to capture disease-causing viruses and bacteria from aerosols emitted across the entire respiratory tract, paired with a buffer tube containing a pathogen-stabilizing solution. After collection, the filter is eluted into the buffer and processed through widely adopted commercial molecular PCR platforms — including QIAsymphony from Qiagen, ELITe InGenius from ELITech, and the RespiFinder 2SMART 24-plex panel from Pathofinder — enabling labs to integrate Avelo into existing diagnostic workflows without replacing capital equipment.

Avelo's go-to-market is B2B and sales-led, targeting hospitals, clinics, and clinical laboratories that need alternative sampling methods for patients who cannot produce sputum or tolerate nasopharyngeal swabs — a population the company estimates at up to 50% of lower respiratory tract infection cases. The company has built a clinical-evidence base through collaborations with academic medical centers including University Hospital Basel (AeroCAP study, 63 adults, 85% pathogen detection with 100% specificity), Goethe University Frankfurt (respiratory virus workflow with multiple PCR platforms), Heidelberg University Hospital (Pseudomonas aeruginosa in cystic fibrosis), and Stellenbosch University (tuberculosis feasibility). It is also a member of the Horizon Europe-funded B-Path Consortium.

The revenue model is hardware-led: Avelo sells the AveloMask Kit as a medical device to healthcare institutions, generating recurring consumable revenue from the buffer tubes used in each test. Pricing is not publicly disclosed and is quote-based. As of the available data, Avelo has raised approximately CHF 2.4 million in total (a CHF 2.2M seed led by OCCIDENT in September 2022, plus earlier Venture Kick and IMD Startup Competition awards), holds BSI ISO 13485:2016 certification, and operates with a core team of roughly seven people — positioning the company at the clinical validation and pre-commercial stage rather than scaled commercial distribution.

Name

Avelo

Legal name

Avelo AG

Website

https://avelolife.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Avelo AG is a Swiss medical device company developing the AveloMask Kit, a non-invasive breath aerosol collector that captures respiratory pathogens for downstream molecular PCR testing, serving hospitals, clinics, and clinical laboratories diagnosing tuberculosis, pneumonia, cystic fibrosis pathogens, and respiratory viruses.

Ownership category

akta.pro rank

Product category

Respiratory Diagnostics Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Noninvasive Ventilation Interfaces & Consumables (Masks, Tubing, Humidifiers, Filters) (HLAHAGAG)

akta.pro secondary industry

Nebulizers & Aerosol Drug Delivery Systems (HLAHAIAJ)

Keywords

• Breath diagnostics
• Respiratory pathogen detection
• Non-invasive sampling
• Infectious disease diagnostics
• Medical device kits

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. AveloMask Kit Sales: Sale of breath sampling kits consisting of mask and buffer tubes to healthcare facilities, hospitals, and clinical laboratories for respiratory disease diagnostics.
2. Consumables (Buffer Tubes): Recurring consumable revenue from buffer tubes used in the AveloMask sampling process.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Avelo AG develops and sells the AveloMask Kit, a breath aerosol collector consisting of a special mask with an integrated filter and a pathogen-stabilizing buffer tube. The kit enables non-invasive collection of respiratory pathogens (viruses and bacteria causing tuberculosis, pneumonia, and other respiratory infections) from exhaled breath, with the captured sample transferable into existing molecular PCR diagnostic workflows. The product is sold B2B to hospitals, clinical laboratories, and academic medical centers as a CE-marked in-vitro diagnostic medical device.

Product overview

Avelo offers the AveloMask Kit, a single unified product for non-invasive breath sampling in respiratory disease diagnostics. The kit comprises the AveloMask (a specialized mask with an integrated filter) and a buffer tube with pathogen-stabilizing solution. The system works with existing molecular PCR tests and laboratory diagnostic platforms to enable detection of respiratory pathogens including tuberculosis, pneumonia, and viruses from exhaled breath aerosols. The AveloMask enables diagnosis for patients who cannot provide sputum samples, expanding access to approximately 50% of patients unreachable by existing sampling methods.

Differentiator

Problem solved

Functional benefit

Brands

• AveloMask: Breath aerosol collector device - a mask and buffer tube kit for non-invasive breath sampling used to diagnose respiratory infectious diseases including tuberculosis, pneumonia, and respiratory viruses.

Products and services

• AveloMask Kit A complete breath sampling kit consisting of a special mask with an integrated filter and a buffer tube with pathogen-stabilizing solution. The kit enables non-invasive collection of respiratory pathogens (viruses and bacteria causing tuberculosis, pneumonia, and other respiratory infections) from exhaled breath aerosols and is designed to work with existing commercial molecular PCR tests for diagnosis of respiratory infections. Sold to hospitals, clinical laboratories, and academic medical centers.

Quantifiable outcome

• AveloMask enables diagnosis for up to 50% of patients who cannot be reached by existing sampling methods
• +2 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• University Hospital BaselcoreStrategic or Co-development PartnerConducted AeroCAP prospective two-center study with 63 adults demonstrating AveloMask's effectiveness for LRTI detection. Prof. Dr. Michael Osthoff presented results at ESCMID Global 2026.
• Institute of Medical Virology at Goethe University Frankfurt (Ciesek group)coreStrategic or Co-development PartnerEstablished robust laboratory workflow integrating AveloMask with QIAsymphony, ELITe InGenius, and RespiFinder 2SMART platforms. Detected SARS-CoV-2, influenza, and rhinovirus from breath samples.
• Heidelberg University HospitalcoreStrategic or Co-development PartnerConducted clinical study evaluating AveloMask for Pseudomonas aeruginosa detection in adults with Cystic Fibrosis. Results presented at DZIF Annual Meeting 2026.
• Stellenbosch University (CLIME Research Group)coreStrategic or Co-development PartnerPresented AveloMask Kit tuberculosis study results at the Union Conference in Copenhagen. Showcased feasibility of capturing Mycobacterium tuberculosis from exhaled breath.
• B-Path Consortium (Horizon Europe)coreStrategic or Co-development PartnerHorizon Europe consortium focused on developing novel technologies for detecting respiratory pathogens from exhaled breath. Part of the B-Path project advancing non-invasive sampling for infectious disease diagnostics and surveillance.
• Qiagen (QIAsymphony)coreTechnology or IntegrationAveloMask workflow integrated with QIAsymphony platform for nucleic acid extraction, enabling seamless integration into existing laboratory diagnostics.
• ELITech (ELITe InGenius)coreTechnology or IntegrationAveloMask workflow integrated with ELITe InGenius extraction platform for clinical diagnostics compatibility.
• Pathofinder (RespiFinder 2SMART)coreTechnology or IntegrationAveloMask samples compatible with RespiFinder 2SMART 24-plex PCR panel for comprehensive respiratory pathogen detection.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Hologic: Major molecular diagnostics player with the Panther system and Panther Fusion respiratory assays; relevant incumbent competitor and potential integration partner for AveloMask workflows.
• Cepheid (Danaher): Established molecular diagnostics company with the GeneXpert system widely used for respiratory pathogen detection, representing the incumbent PCR workflow that AveloMask integrates into at the front-end sample collection stage.
• bioMérieux (BioFire Diagnostics): Global diagnostics incumbent whose BioFire FilmArray respiratory panels define the standard for multiplex respiratory pathogen PCR testing; AveloMask is designed to feed into this category of downstream molecular tests.

Emerging players

• Specific Diagnostics: Emerging player in rapid phenotypic antimicrobial susceptibility testing with relevance to respiratory infection management; partially overlapping with Avelo's AMR stewardship value proposition.
• Respiratory Diagnostics (clinical sputum-based PCR players): Smaller emerging respiratory diagnostics companies whose sample collection and PCR workflows compete with AveloMask's non-invasive breath approach in the same end-customer base.

Others

• Qiagen: Technology and integration partner whose QIAsymphony platform is validated with AveloMask, and whose respiratory PCR assays (e.g., QIAstat-Dx) compete in the downstream respiratory diagnostics market.
• PathoFinder: Niche molecular diagnostics company whose RespiFinder 2SMART 24-plex PCR panel is validated with AveloMask; serves as both integration partner and adjacent diagnostic assay provider in the respiratory space.
• ELITech Group: Diagnostic instrument manufacturer whose ELITe InGenius platform is integrated with AveloMask; ELITech's respiratory PCR menu overlaps with the downstream testing category AveloMask supports.

Direct peers

• Owlstone Medical: UK-based company developing breath-based diagnostic platforms (Breath Biopsy) for respiratory and other diseases. Closest direct peer to Avelo in terms of breath-sampling approach and target customer base of hospital and clinical labs.
• Avisa Pharma: US-based company developing breath-based diagnostics with a focus on tuberculosis detection, directly overlapping with Avelo's TB use case and similar breath-sampling value proposition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/avelolife

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avelo